17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.

Abstract:

:Intramuscular 17 α-hydroxyprogesterone caproate (Makena(®)), a synthetic progestin, is indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Makena(®) reduces the risk of preterm birth in this patient population, and is associated with improvements in certain fetal/neonatal outcomes. The use of this US FDA-approved formulation of 17 α-hydroxyprogesterone caproate reduces the inherent risks associated with the use of pharmacy-compounded formulations of the drug.

journal_name

Clin Drug Investig

authors

Hines M,Lyseng-Williamson KA,Deeks ED

doi

10.1007/s40261-013-0060-6

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

223-7

issue

3

eissn

1173-2563

issn

1179-1918

journal_volume

33

pub_type

杂志文章